Mirati Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mirati Therapeutics, Inc.
Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.
Last week, the Swiss major gave a glimpse into the next wave of innovation coming out of its labs in key areas such as osteoarthritis, pancreatic cancer and food allergy. Scrip has been taking a detailed look at the highlights.
The biotech also provided an update on its pursuit of approval for adagrasib, a KRAS G12C inhibitor that is likely to compete against Amgen’s first-to-market Lumakras.
While revenue beat consensus, the company slightly lowered its 2021 guidance due to pandemic impacts, but the closely watched KRAS G12C inhibitor exceeded expectations in its first full quarter.
- Other Names / Subsidiaries
- MethylGene Inc.